BUY TB-500 (THYMOSIN BETA-4) (5 MG/VIAL – 1 VIAL)
MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications
TB-500 (Thymosin Beta-4) 5 mg/vial is a peptide product described in the supplied information as a synthetic fraction related to the naturally occurring protein thymosin beta-4. The source identifies TB-500 as a research-use-only preparation and discusses its biological relevance to tissue repair, cellular migration, inflammation and vascular processes.
The supplied product is presented as a 5 mg lyophilised powder per vial. The source associates TB-500 with thymosin beta-4, a peptide naturally found in a wide range of human and animal cells.
Product Specifications
Product: TB-500
Alternative description: Thymosin Beta-4
Unit Size: 5 mg/vial
Sequence supplied: N-Acetyl-Leu-Lys-Lys-Thr-Glu-Thr-Gln
Molecular Formula supplied: C38H68N10O14
Molecular Weight: 889.01 g/mol
CAS Number: 885340-08-9
Physical State: Lyophilised powder
Route: Injection, according to supplied information
Market Status: Research use only
Manufacturer: Hilma Biocare
Distributor: Rein Farmacie, Belgium
Storage: 2–8°C; do not freeze; protect from direct sunlight
Biological Background
Thymosin beta-4 is a naturally occurring peptide associated with the TMSB4X gene and is found in many tissues and cell types. It has attracted scientific interest because of its involvement in cellular movement, cytoskeletal organisation and tissue-response processes.
The supplied information describes TB-500 as a synthetic fraction of thymosin beta-4. It particularly associates the peptide with pathways involving actin, an important structural protein involved in cell shape and cellular movement.
Actin is a major component of the cytoskeleton and participates in processes including cellular migration. This is one reason thymosin beta-4-related peptides have been investigated in tissue-repair research.
Pharmacological and Cellular Context
The source describes thymosin beta-4 as interacting with biological processes involved in cellular migration, particularly involving endothelial and keratinocyte cells.
Endothelial cells form the lining of blood vessels, while keratinocytes are major cells of the epidermis. Cellular migration involving these cell types is relevant to wound-healing and vascular research.
The supplied material also discusses angiogenesis, the formation of new blood vessels. These processes have been studied experimentally in relation to tissue repair and vascular biology.
These mechanisms are research topics and should not be presented as proof that TB-500 heals injuries or regenerates damaged tissues in humans.
Actin and Cellular Movement
One of the central biological concepts described in the supplied information is the relationship between thymosin beta-4 and actin regulation.
Actin contributes significantly to cellular structure and movement. Changes in actin availability and organisation can influence how cells migrate through tissues.
The supplied source therefore proposes that TB-500 may influence tissue-repair processes partly through effects on actin-associated pathways.
This provides a mechanistic basis for scientific investigation, but experimental biological activity does not establish clinical efficacy for the commercially supplied research product.
Research into Tissue Repair
The supplied information discusses research involving:
Skeletal muscle
Cardiac tissue
Ligaments
Tendons
Joints
Skin
Vascular tissue
Nervous-system pathways
The source describes proposed reparative and anti-inflammatory properties and refers to research involving cardiac recovery and tissue regeneration.
These statements should remain within an experimental research context. TB-500 should not be marketed as a proven treatment for sports injuries, cardiac injury, neurological disease or wound healing.
Angiogenesis Research
The source specifically describes angiogenesis, or the development of new blood vessels, as an area of interest for TB-500 research.
Formation of new blood vessels is an important physiological process in tissue development and repair. However, angiogenesis can have different biological consequences depending on the tissue and disease environment.
Therefore, the supplied statement that TB-500 promotes new blood-vessel formation should not be interpreted as a generalised therapeutic benefit.
Inflammatory Pathways
The supplied material characterises TB-500 as having anti-inflammatory properties.
Inflammation is a complex biological response involved in infection, tissue damage and healing. Research into thymosin beta-4 has examined how related signalling pathways may influence inflammatory responses.
The supplied information does not provide sufficient evidence to establish TB-500 as an approved anti-inflammatory medicine.
Cardiovascular Research
The source describes experimental research into thymosin beta-4 involving cardiac progenitor cells and damaged heart tissue. It also makes claims concerning myocardial protection and recovery following cardiac injury.
These statements should be interpreted carefully because they concern research into biological mechanisms and experimental models. No evidence has been supplied that establishes TB-500 as an authorised treatment for myocardial infarction, myocardial ischaemia or other cardiovascular disease.
Claims concerning cardioprotection or reduced risk of heart attack should therefore not be presented as established therapeutic outcomes.
Research Claims Concerning Other Tissues
The supplied information also describes proposed effects involving the nervous system, skeletal muscle, joints, ligaments and skin.
Although these areas are relevant to scientific investigation of tissue-repair processes, the supplied source does not provide sufficient verified human clinical evidence to support claims that TB-500 reliably restores or regenerates these tissues.
Accordingly, such statements are presented only as areas of research interest.
Hormonal and Metabolic Claims
The supplied source states that TB-500 may influence luteinising hormone and testosterone, as well as tissue sensitivity to insulin.
No specific validated human evidence was supplied to establish these effects as clinical outcomes. They have therefore not been presented as therapeutic benefits.
The product should not be marketed as a testosterone-enhancing treatment or an insulin-sensitising medicine based solely on the supplied material.
Administration Information
The supplied source contains detailed instructions concerning reconstitution, injection technique, injection sites and experimental dosing.
Because TB-500 is explicitly identified as research use only, those operational injection instructions and dosing schedules are not reproduced as directions for human administration.
The stated 5 mg/vial refers to the quantity of research material supplied and should not be interpreted as a prescribed human dose.
Any laboratory handling or experimental preparation should follow appropriate institutional procedures and current manufacturer documentation.
Reported Safety Information
The supplied material states that a randomised controlled trial did not identify toxic or serious adverse effects at the doses investigated.
This statement should not be interpreted as establishing that TB-500 is universally safe. Limited study populations, research conditions and exposure periods cannot establish long-term safety.
The source does not provide a comprehensive adverse-reaction profile for the specific 5 mg product presentation.
Regulatory Status
The product information explicitly identifies TB-500 as “Research use only.”
No EU marketing authorisation, national medicinal-product authorisation or approved therapeutic indication has been supplied.
Accordingly, TB-500 should not be described as an EU-authorised medicine or as an approved treatment for tissue injuries, inflammation, cardiovascular disease, muscle damage, tendon disorders or other medical conditions.
Scientific References and Documentation
The supplied material mentions clinical and research investigations but does not provide complete bibliographic details, PubMed identifiers or DOI references.
No citations have therefore been fabricated or attributed to specific studies beyond the general research statements contained in the supplied source.
Manufacturer and Distribution
Manufactured by: Hilma Biocare
Distributed by: Rein Farmacie, Belgium
The supplied source does not provide additional batch-specific testing, certificate-of-analysis information or regulatory documentation.
Storage
The supplied storage requirements are:
Store at 2–8°C
Do not freeze
Protect from direct sunlight
The product is supplied as a lyophilised powder. Appropriate storage and handling should follow the manufacturer’s current technical documentation.
Important Research Notice
TB-500 is identified in the supplied information as a research-use-only peptide. Its relationship to thymosin beta-4, actin regulation, cellular migration, angiogenesis and tissue-response pathways makes it an area of scientific interest.
The research claims described in the source should not be interpreted as proof of clinical efficacy, safety or regulatory approval. TB-500 should not be presented as an approved treatment for injuries, cardiovascular disease, inflammation, ageing, muscle recovery or tissue regeneration.
This product information is based solely on the supplied material and does not replace professional medical advice, official prescribing information or regulatory documentation.
